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Abstract
Objectives: In Scotland, legislation was implemented in March 2006 prohibiting smoking in all wholly or partially enclosed
public spaces. We investigated the impact on attempts to quit smoking and smoking prevalence.
Methods: We performed time series models using Box-Jenkins autoregressive integrated moving averages (ARIMA) on
monthly data on the gross ingredient cost of all nicotine replacement therapy (NRT) prescribed in Scotland in 2003–2009,
and quarterly data on self-reported smoking prevalence between January 1999 and September 2010 from the Scottish
Household Survey.
Results: NRT prescription costs were significantly higher than expected over the three months prior to implementation of
the legislation. Prescription costs peaked at £1.3 million in March 2006; £292,005.9 (95% CI £260,402.3, £323,609, p,0.001)
higher than the monthly norm. Following implementation of the legislation, costs fell exponentially by around 26% per
month (95% CI 17%, 35%, p,0.001). Twelve months following implementation, the costs were not significantly different to
monthly norms. Smoking prevalence fell by 8.0% overall, from 31.3% in January 1999 to 23.7% in July–September 2010. In
the quarter prior to implementation of the legislation, smoking prevalence fell by 1.7% (95% CI 2.4%, 1.0%, p,0.001) more
than expected from the underlying trend.
Conclusions: Quit attempts increased in the three months leading up to Scotland’s smoke-free legislation, resulting in a fall
in smoking prevalence. However, neither has been sustained suggesting the need for additional tobacco control measures
and ongoing support.
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Introduction
In Scotland, legislation was implemented at the end of March
2006 prohibiting smoking in all wholly or partially enclosed public
spaces. The primary aim of the legislation was to protect non-
smokers from exposure to secondhand smoke. A comprehensive
evaluation of the impact of the legislation [1] has found that this
aim has been largely achieved, with reductions in exposure to
secondhand smoke among bar workers [2], the adult general
population [3,4], and children [5], accompanied by improved
respiratory health among bar workers [6], and reductions in
hospitalisations for childhood asthma [7] and acute coronary
syndrome [8]. Studies on the impact of workplace prohibitions
suggest that smoking restrictions can also encourage smoking
cessation and, thereby, reduce smoking prevalence [9]. It has been
suggested that comprehensive legislation covering all public places
may have an even greater effect on smoking behaviour [10]. Use
of nicotine replacement therapy (NRT) is a good proxy indicator
of quit attempts among smokers. A time series analysis of over-the-
counter (OTC) NRT sales revealed that Scotland’s smoke-free
legislation was associated with a short-term increase in OTC sales
of NRT [11]. However, OTC sales represent only a small
proportion of NRT usage. Also, only 2–3% of quit attempts are
successful [12]. Therefore, we analysed the impact of the Scottish
legislation on NRT prescriptions and smoking prevalence.
Methods
Nicotine replacement therapy
In the United Kingdom, there were a number of changes in
NRT provision in 2001 and 2002 including making OTC NRT
accessible from non-pharmacy retail outlets and making all NRT
products available on NHS prescriptions [13]. Therefore, we
analysed NRT data from January 2003 onwards. The Practitioner
Services Division of the Scottish National Health Service is
responsible for the pricing and processing of all prescriptions that
are dispensed outside of hospital, either by community pharmacies
or dispensing practices. They also receive information on
prescriptions that are issued in Scotland but are dispensed
elsewhere in the United Kingdom. We obtained data on the
monthly gross ingredient costs of nicotine replacement therapy
(NRT) dispensed over a seven year period from January 2003 to
December 2009 inclusive; the latter equated to the most recent
data available at the time of analysis. The gross ingredient cost is
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payments made to those prescribing or dispensing the drug. It
includes any costs fully or partially reimbursed via prescription
charges. The data covered all community-based prescribing
sources including general practitioners, the public health service,
prescribing nurses, the minor ailment services located in
community pharmacies and practice pharmacies. Two sources of
NRT prescriptions were not active over the whole study period.
NRT was only prescribed by the Minor Ailments Service until the
middle of 2007 and by the Public Health Service from 2008.
Prescriptions from all sources were included in the overall model
for completeness. The data also included prescriptions issued by
hospital doctors but dispensed in the community. The data did not
cover nicotine replacement therapy purchased over the counter
without prescription. These data have already been reported
elsewhere [11].
Smoking prevalence
The Scottish Household Survey (SHS) is funded by the Scottish
Government and is a continuous, large-scale social survey of
Scottish households and their occupants. The multi-stage sampling
is structured to be nationally representative every quarter.
Therefore, the data are only available quarterly. Around 26,000
individuals are invited to participate each year and annual
response rates are in the range of 66% to 69%, providing
information on around 4,000 individuals every quarter. Question-
naires include information on self-reported current smoking status
and are completed by fieldworkers using computer aided personal
interviewing (CAPI). The Scottish Household Survey provided
quarterly data on smoking prevalence over more than 11 years,
from January 1999 to September 2010 inclusive; the latter equated
to the most recent data available at the time of analysis. Because
the smoking prevalence data were only available quarterly,
truncation of the study period to January 2003 to December
2009, consistent with NRT data, would have considerably reduced
the number of data points and hence statistical power.
Statistical analyses
Data from the six prescribing sources were aggregated to
provide one overall time series. We analysed the overall
prescribing data and the smoking prevalence data using Box-
Jenkins autoregressive integrated moving average (ARIMA)
models [14]. ARIMA was considered preferable to standard
interrupted time series models, in that complex time series patterns
can be modelled parsimoniously, seasonality within the data is
easily handled, past observations are allowed to influence future
observations and well established statistical techniques have been
developed that allow the impact of interventions on future
behaviour to be accurately described and quantified [15].
Individual months vary in the numbers of dispensing days they
contain. Therefore, the prescribing series was adjusted for ‘‘trading
day’’ effects. We investigated a number of possible models using
autocorrelation and partial autocorrelation functions before
checking the stationarity properties of both the prescribing and
prevalence series using unit root tests [16]. The modelling strategy
consisted of initially modelling the whole series to obtain an
adequate preliminary model and then modelling and testing the
effect of the ban [17]. The Akaike information criterion (AIC)
statistic was used to select the most appropriate and parsimonious
models prior to testing the intervention hypothesis [18–20]. The
form of the intervention effect was hypothesised from the time
plots of the series. All fitted models were subjected to standard
diagnostic checking to ensure that the residuals of the fitted models
were not significantly different from those expected from white
noise or a random series [21]. We compared the fit from the
predicted model and the observed series using the root mean
squared error as well as the adjusted R
2 measure for ease of
interpretation. All analyses were undertaken using Stata V11.2
software (STATA Corp, College Station, Texas, URL http://
www.stata.com).
This study did not require ethics committee approval. We used
secondary data, provided to us as an anonymised and aggregated
extract. Identification of individual participants was not possible.
Therefore, contacting individual participants to obtain consent
was neither necessary nor required.
Results
Prescriptions for nicotine replacement therapy
Over the seven year period, the gross ingredient costs of
prescribed NRT amounted to £43.3 million. Of these, £34.5
million (79.7%) were due to prescriptions issued by general
practitioners, £3.4 million (7.9%) by the public health service
(PHS), £2.8 million (6.5%) by prescribing nurses, £1.4 million
(3.2%) by the minor ailment services located in community
pharmacies, £49,765 (0.1%) by practice pharmacies, £16,932
(0.04%) by hospital doctors and £1.2 (2.8%) million by NHS
smoking cessation clinics based in community pharmacies. There
was a clear seasonal pattern. Median monthly prescription costs
peaked in March, coinciding with No Smoking Day in the United
Kingdom, and troughed in December (Figure 1). The median cost
of NRT prescriptions issued in March (£747,399) was 88.8%
higher than those issued in December (£395,955).
Figure 2 presents the observed time trends in NRT prescription
costs together with the expected time trends. The expected trends
are derived from the monthly averages of the pre-ban years (2003–
2005) projected beyond 2005. It demonstrates that prescription
costs rose dramatically above the pre-ban expected level in March
2006 and then fell after implementation of the legislation before
finally reverting to pre-ban expected levels. The pre-legislation rise
in prescription costs was not specific to one prescribing source. For
the prescribing series the model selected was a multiplicative
seasonal ARIMA (SARIMA) with two autoregressive parameters
and one autoregressive parameter at the seasonal lag (Table 1).
The initial AIC statistic was 2128.9. The Ljung-Box Q statistic for
the residuals of the series was 11.43 (p=0.49) at 12 lags and 18.48
(p=0.78) at 24 lags indicating that the residuals were ‘‘white
noise’’ and the model was a good fit to the series. The adjusted R
2
for the predicted model fit was 85.5%. To model the introduction
of the ban, as well as the anticipatory effect on quit attempts which
resulted in two large outliers in January and February of 2006, we
included in the SARIMA model dummy variables for January,
February and March 2006 as well as a decay parameter, defined as
the first lag of the series, from March 2006 onwards. Figure 3
shows the observed and predicted time series using this final
intervention model, and demonstrates that the final model was a
very good fit for the observed series (adjusted R
2=90.8%)
(Table 1). The results of the diagnostic tests applied to the
residuals of the model were also reassuring (Ljung-Box Q statistic:
3.00, p=1.00 at lag 12 and 9.51, p=1.00 at lag 24). The AIC fell
to 2060.4 indicating that the additional parameters improved the
fit of the final model (Table 1).
NRT prescription costs increased to levels significantly higher
than the monthly norms in the three months leading up to
implementation of the legislation (Figure 2). NRT prescriptions
issued in January and February 2006 were £159,205.3 (95% CI
£147,857.7, £170,552.9, p,0.001) and £193,216.6 (95% CI
£143,562.1, £242,871.2, p,0.001) respectively higher than their
Smoking Prevalence and Quit Attempts
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doi:10.1371/journal.pone.0026188.g001
Figure 2. Observed and expected monthly gross ingredient costs of nicotine replacement therapy prescribed in Scotland (2003–
2009).
doi:10.1371/journal.pone.0026188.g002
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March 2006. This was £292,005.9 (95% CI £260,402.3,
£323,609, p,0.001) higher than the March norm. Overall
prescription costs for 2006 were £7.4 million, 13.8% higher than
the 2003–2005 average annual costs of £6.5 million. The estimate
of the decay parameter was 0.74 (95% CI 0.65, 0.83, p,0.001).
That is, following implementation of the legislation, prescription
costs attributable purely to the introduction of the smoking ban fell
Table 1. Time series regression analyses of monthly nicotine replacement therapy gross ingredient costs.
Initial model Final model
*
coefficient (95% CI) P value Coefficient (95% CI) P value
Monthly, bimonthly and seasonal effects**
1 month lag 1.22 (1.03, 1.41) ,0.001 0.30 (0.10, 0.50) 0.003
2 month lag 20.35 (20.60, 20.10) 0.006 0.26 (0.05, 0.46) 0.013
12 month lag 0.71 (0.59, 0.83) ,0.001 0.85 (0.74, 0.97) ,0.001
Legislation effect
March 2006 effect - - 292,005 (260,402, 323,609) ,0.001
Post March 2006 decay effect - - 0.74 (0.65, 0.83) ,0.001
Regression diagnostics
AIC 2,128 - 2,060 -
Q1 statistic 0.68 0.41 0.64 0.42
Q12 statistic 11.43 0.49 3.00 1.00
Q24 statistic 18.48 0.78 9.51 1.00
Adjusted R
2 (%) 85.5 - 90.8 -
RMSE 72,507 - 58,469 -
*Adjusted for change at March 2006 effect, post March 2006 decay effect, and January/February 2006 peaks.
**Derived from autoregressive moving average model.
CI confidence interval; AIC Akaike Information Criterion; RMSE root mean square error.
doi:10.1371/journal.pone.0026188.t001
Figure 3. Observed and predicted monthly gross ingredient costs of nicotine replacement therapy prescribed in Scotland (2003–
2009).
doi:10.1371/journal.pone.0026188.g003
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implementation of the legislation, prescription costs associated
with its introduction were not significantly different from the
expected 2003 to 2005 pre ban levels, monthly values.
Smoking prevalence
The prevalence of self-reported smoking fell by approximately
8.0%, from 31.3% in January–March 1999 to 23.7% in July–
September 2010, with a steep decline in prevalence in the quarter
preceding implementation of the legislation, followed by a return
to levels more consistent with the underlying trend (Figure 4) after
approximately one year. The initial model selected for the
prevalence data was an ARIMA with one moving average
parameter at lag 2 (Table 2). The AIC statistic was 140.3 and
the Q statistics for residuals at lags 4 and 8 were 0.44 (p=0.98)
and 5.12 (p=0.74) respectively. The adjusted R
2 measure of
predicted versus observed fit was 79.4%. The intervention effect of
the smoking ban was modelled as being of temporary duration by
adding to the model a decay parameter and dummy variable for
October–December 2005. The AIC statistic for the final
intervention model was 138.5 with the predictive ability of the
model improving slightly to an adjusted R
2 of 79.6%. Q statistics
for residual autocorrelation were 0.38 (p=0.54) at lag one, 1.22
(p=0.87) at lag 4 and 3.43 (p=0.90) at lag 8. Figure 4 shows the
observed and predicted time series using this model. The model
produced a coefficient for the post legislation period dummy
variable of 21.70 (95% CI 22.38, 21.02, p,0.001) indicating
that in October–December 2005 immediately prior to the
introduction of the ban prevalence fell by 1.70% more than
expected from the underlying trend. The magnitude of the decay
parameter, 20.08, (95% CI 20.38, 0.22) indicates that this effect
was short lived with prevalence returning to its long term trend by
the last quarter of 2006.
Discussion
Summary of main findings
In Scotland, smoke-free legislation was associated with a sharp
increase in quit attempts, as measured by NRT prescriptions. The
increase preceded the legislation by around three months and was
accompanied by a 1.7% absolute reduction in smoking prevalence.
However, the early benefits have not been sustained, with NRT
prescriptions falling to pre-legislation levels within one year of
implementation and smoking prevalence also reverting to the
underlying trend. This suggests that the prospect of smoke-free
legislation accelerated quit attempts and successful quitting among
those already planning to quit, but reduced the pool of smokers
who were ready to quit and, therefore, the number of quit
attempts made in the following months.
Comparison with other studies
Our findings in relation to NRT prescriptions are consistent
with a shorter (2004–2006) time series study of OTC sales of NRT
in Scotland which reported that sales increased significantly in the
first six months of 2006 but fell thereafter [11]. This study only
had information up to one year following the legislation and did
not include prescribed NRT. Our study demonstrates that the
increase in OTC sales reported in the earlier study cannot be
explained by a shift from prescribed NRT to OTC sales, since
both increased in the pre-legislation period. Furthermore, our
longer time series confirms that, following legislation, NRT use
reverted to, and has remained at, pre-legislation levels. In New
York, there was also a short-term increase in OTC sales after
smoke-free workplace law was introduced, with increases greatest
in the week following implementation then declining rapidly
afterwards, although pharmacies located in low income areas
reported larger and more persistent increases [22]. Scottish adult
Figure 4. Observed and predicted quarterly smoking prevalence in Scotland (January 1999–September 2010).
doi:10.1371/journal.pone.0026188.g004
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aspirin trial, also reported more quit attempts in the quarter
preceding the Scottish legislation, with the mean quit rate
increasing from a baseline of 2.3% to 5.1% [23]. Among those
who quit, nearly half reported that the legislation had encouraged
them to attempt quitting. In a recent study, NRT and bupropion
prescribed by general practitioners in England increased in the
nine months prior to legislation and fell thereafter [24]. The study
did not include NRT prescribed via other routes which, from our
results, may account for up to 20% of prescriptions.
The 1.7% absolute reduction in smoking prevalence that followed
implementation of the Scottish smoke-free legislation is smaller than
reductions previously reported following workplace restrictions. In
their meta-analysis, Fichtenberg and Glantz, reported a 3.8% (95%
CI 2.8, 4.7) absolute reduction in smoking prevalence, as well as a
mean reduction of 3.1 (95% CI 2.4, 3.8) cigarettes smoked per day
[9]. Most of the studies included in the review controlled for some
potentialconfounding factors,butmayhave beensubjecttoselection
bias in terms of worker profile and the type of worksite; for example
over-representation of health care services. More recently, however,
a study of the Italian smoking ban, found that smoking prevalence
fell by 1.9% from 26.2% to 24.3%, a figure more commensurate
with our findings. The Italian study also reported that the mean
number of cigarettes smoked per day fell from 15.4 to 13.9, with the
fall most apparent among younger men [25].
Strengths of our study
Our study has a number of strengths. We used a robust and
flexible modelling approach. We had Scotland-wide data from all
prescribing sources, including prescriptions issued in Scotland but
dispensed elsewhere. We had data over a seven year period,
including three years following the legislation, reducing the risk of
random variation due to short follow-up. We also had nationally
representative quarterly data on smoking prevalence.
Limitation of our study
The main limitation of our study was the use of overall NRT
prescribing as a proxy measure of the numbers of individuals
attempting to quit. We did not have access to individual level data
on the frequency or duration of NRT use, nor can we identify
individuals who attempted to quit on more than one occasion over
the seven year period. However, this is unlikely to have introduced
a systematic error. Also, we cannot infer whether the reduction in
smoking prevalence was due entirely to increased quit attempts or
also, in part, to increased success among those who attempted to
quit. It is plausible that prohibition of smoking in public places
may assist continuation of abstinence.
Conclusions
The World Health Organisation’s Framework Convention on
Tobacco Control stipulates that smoke-free legislation should be
introduced as part of a comprehensive programme of tobacco
control because this approach may be more successful at reducing
smoking prevalence [26]. Indeed, in a study in Melbourne,
Australia, smoke-free restaurants did not have an independent
effect after adjustment for other tobacco control measures [27].
Similarly, in a correlational study of 18 European countries there
was no significant association between public place bans and age-
sex standardised quit ratio (former smokers : ever smokers) when
adjusted for price controls, advertising bans, educational cam-
paigns, health warnings and cessation interventions [28]. In
contrast, Grassi et al demonstrated that the effectiveness of
smoking cessation interventions was increased following introduc-
tion of the Italian smoke-free legislation [29]. The odds of
continued smoking at 12 months were reduced by 41% among
those undergoing group counselling therapy and by 52% among
those receiving bupropion as well as counselling. They demon-
strated that the effect was mediated via an increase in motivation.
Similarly, a study in the USA demonstrated that comprehensive
tobacco control programmes were more effective than price
controls used in isolation [30]. In Scotland, smoke-free legislation
was one component of a comprehensive tobacco control strategy
that had been developed and implemented over the preceding
eight years. Scotland’s tobacco control strategy is one of the most
comprehensive in Europe and includes well developed smoking
cessation services and NRT prescribing provided by the National
Table 2. Time series regression analyses of quarterly smoking prevalence.
Initial model Final model*
coefficient (95% CI) P value coefficient 95% CI P value
Six monthly effect**
2 quarter moving average 20.35 (20.684, 20.007) 0.045 20.34 (20.67, 20.10) 0.044
Legislation effect
October/December 2005 effect - - 21.70 (22.38, 21.02) ,0.001
Post December 2006 decay effect - - 20.08 (20.39, 0.22) 0.59
Regression diagnostics
AIC 140.3 - 138.5 -
Q1 statistic 0.26 0.61 0.38 0.54
Q4 statistic 0.44 0.98 1.22 0.87
Q8 statistic 5.12 0.74 3.43 0.90
Adjusted R
2 (%) 79.4 - 79.6 -
RMSE 1.03 - 0.99 -
*Adjusted for change at March 2006 effect, and post March 2006 decay effect.
**Derived from autoregressive moving average model.
CI confidence interval; AIC Akaike Information Criterion; RMSE root mean square error.
doi:10.1371/journal.pone.0026188.t002
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the legislation there were two high profile television campaigns.
The first ran from September to December 2005 and promoted
smoking cessation services and the second ran between January
and March 2006 and highlighted the risks associated with
exposure to secondhand smoke. During both campaigns calls to
Smokeline, the national smoking telephone helpline, greatly
exceeded seasonal norms [personal communication: Lesley
Cunningham, Essentia Group, Group 2010]. There have been
no further campaigns since implementation of the legislation. Our
results suggest that the introduction of smoke-free legislation can
encourage changes in smoking behaviour. However, if the early
benefits are to be sustained in the longer term, legislation needs to
be part of a comprehensive programme in which other measures,
such as smoking cessation support and media awareness and
education campaigns, not only precede legislation but also
continue thereafter.
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